Overview

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

Status:
Completed

Trial end date:
2005-02-01

Target enrollment:

Participant gender:

Summary

This trial will explore the various advantages and possible disadvantages of pioglitazone and insulin glargine when added to monotherapy. Glycemic control, hypoglycemia, weight, lipid profiles, quality of life and cost will be studied given a comprehensive set of data that may help future treatment decisions.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Insulin
Insulin Glargine
Insulin, Globin Zinc
Metformin
Pioglitazone